Loading
NASDAQHealthcareMedical - Specialties
Latest quote
$13.97
+$0.04 · +0.29%
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Previous close
$13.97
+$0.04 · +0.29%
Regular session · ET · Market data may be delayed.
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Day range
Current $13.97
52-week range
Current $13.97
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
47
Fair Value
Sentiment
55
Mixed
Risk
62
High Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Day range
Current $13.97
52-week range
Current $13.97
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.73B USD | 2.78B USD | 3B USD | 3.27B USD | 1.7B USD |
| Cost of goods sold | 1.46B USD | 1.5B USD | 1.5B USD | 1.33B USD | 420.3M USD |
| Gross profit | 1.27B USD | 1.29B USD | 1.5B USD | 1.94B USD | 1.28B USD |
| Research and development | 186.2M USD | 218.7M USD | 246.8M USD | 187.9M USD | 95.7M USD |
| Selling, general, and administrative | 746.3M USD | 766.8M USD | 763.2M USD | 621M USD | 239.6M USD |
| Operating expenses | 2.19B USD | 3.25B USD | 1.36B USD | 1.09B USD | 372.3M USD |
| Interest income | — | — | 2.2M USD | 1.3M USD | 300K USD |
| Interest expense | 177.6M USD | 188.3M USD | 178.9M USD | 74.5M USD | 700K USD |
| Depreciation and amortization | 442M USD | 453.4M USD | 457.2M USD | 283.6M USD | 52.7M USD |
| Operating income | −919.2M USD | −1.96B USD | 139.1M USD | 843.7M USD | 906M USD |
| Net income | −1.13B USD | −2.05B USD | −10.1M USD | 548.7M USD | 704.2M USD |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR60.53M0.05%109.08B USD0.06%$145.34+0.37%
Avantis U.S. Small Cap Value ETFAVUV45.73M0.14%31.49B USD0.25%$126.93+0.52%
Vanguard Morningstar Total Stock Market ETFVTI36.44M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Morningstar Small-Cap ETFVB26.28M0.01%183.4B USD0.03%$300.01+0.05%
iShares Russell 2000 ETFIWM24.31M0.03%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Small-Cap Value ETFVBR16.7M0.02%68.3B USD0.05%$247.11+0.08%
Vanguard Extended Market ETFVXF13.2M0.01%93.7B USD0.05%$242.66+0.14%
iShares S&P Small-Cap 600 Value ETFIJS8.81M0.10%8.24B USD0.18%$137.54+0.63%iShares Core S&P Small-Cap ETFIJRAvantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFiShares S&P Small-Cap 600 Value ETFIJSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
